FDA approves Intersect ENT's next-gen "mini" drug-eluting sinus implant

Tue, 11/06/2012 - 2:10pm
Mass Device

Intersect ENT wins FDA approval for the 2nd in its flagship line of Propel steroid-releasing implants for treatment of chronic sinusitis.

Intersect ENT logo

Drug-delivery devices maker Intersect ENT touted FDA approval for its 2nd-generation Propel mini implant, a smaller version of its previously approved device for treating chronic sinusitis.

The newly approved Propel mini will be offered in select U.S. hospitals this month, with full nationwide launch expected in 2013 alongside a planned sales force expansion, according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.